Publisher
Springer Science and Business Media LLC
Reference84 articles.
1. Bastian, P. J. et al. Insignificant prostate cancer and active surveillance: from definition to clinical implications. Eur. Urol. 55, 1321–1330 (2009).
2. Loeb, S. et al. Overdiagnosis and overtreatment of prostate cancer. Eur. Urol. 65, 1046–1055 (2014).
3. Mahal, B. A. et al. Use of active surveillance or watchful waiting for low-risk prostate cancer and management trends across risk groups in the United States, 2010–2015. JAMA 321, 704–706 (2019).
4. Matoso, A. & Epstein, J. I. Defining clinically significant prostate cancer on the basis of pathological findings. Histopathology 74, 135–145 (2019).
5. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for prostate cancer V.3.2020 (NCCN, 2020).
Cited by
28 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献